IL6 and COVID-19: Patients with COVID-19 exhibit marked activation of inflammatory markers, including abnormal levels of C-reactive protein (CRP), lymphocytes, neutrophils and cytokines, in particular interleukin-6 (IL-6).8,11, –13 These mechanisms may contribute to pulmonary and extrapulmonary injuries12,14 and the control of cytokine dysregulation at an early stage could be beneficial to curb the disease progression.15